FDA Approves Injectable Lenacapavir as Long-Acting HIV Prevention Option:

FDA Approves Injectable Lenacapavir as Long-Acting HIV Prevention Option:

Daily Current Affairs   /   FDA Approves Injectable Lenacapavir as Long-Acting HIV Prevention Option:

Change Language English Hindi

Category : Science and Tech Published on: June 21 2025

Share on facebook

The U.S. FDA has approved injectable lenacapavir as a semiannual HIV prevention method. This follows positive outcomes from PURPOSE 1 & 2 clinical trials in 2024. The WHO welcomed the move, highlighting it as a significant step in expanding HIV prevention options with a long-acting, convenient alternative for vulnerable populations.

Recent Post's
  • India drops to 85th rank in the Henley Passport Index as China climbs to 64th; Indian passport now offers visa-free access to 57 countries.

    Read More....
  • Lxme launches ‘LxmePay’, India’s first women-only UPI app that rewards transactions with digital gold to boost savings.

    Read More....
  • India’s gold reserves cross $100 billion for the first time as global bullion prices rise, making up 14.7% of total forex reserves.

    Read More....
  • India-Japan Fund invests ₹500 crore in Eka Mobility to boost EV manufacturing and strengthen Indo-Japan climate cooperation.

    Read More....
  • IWAI hands over Haldia Multimodal Terminal to IRC Natural Resources under PPP model as part of the Jal Marg Vikas Project.

    Read More....
  • Jyothi Surekha Vennam becomes first Indian woman to win a medal at Archery World Cup Final, clinching bronze in Nanjing.

    Read More....
  • Veteran actor Govardhan Asrani, known for his comic roles in classics like Sholay and Chupke Chupke, passes away at 84.

    Read More....
  • Zoravar Singh Sandhu wins bronze in men’s trap at ISSF Shotgun World Championships 2025 in Athens, marking India’s third world-level medal.

    Read More....
  • CDSCO launches a digital monitoring system to track high-risk pharmaceutical solvents in real time, ensuring safer medicines for all.

    Read More....